Phase 2Data readout

Mivelsiran (ALN-APP)

Cerebral Amyloid Angiopathy

ALNYAlnylam Pharmaceuticals

Expected catalystDecember 31, 2028Company guidance: Dec 31, 2028

Catalyst overview

Event details

Drug or asset: Mivelsiran (ALN-APP)
Development stage: Phase 2
Event type: Data readout
Indication: Cerebral Amyloid Angiopathy

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for Mivelsiran (ALN-APP) in Cerebral Amyloid Angiopathy. The expected timing is based on the latest available company guidance and may change.

Development notes

cAPPricorn-1 trial. Collab w/ Regeneron. 8/1/24 Initiate dosing. 2/25/25- Ongoing evaluation. 07/15/26:- cAPPricorn-1 Ph2 enrollment completed. Initial results expected in 2028.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source